10-K: Vivani Medical's 10-K Filing: Prioritizing Obesity Portfolio and Advancing Clinical Trials

Vivani Medical's 10-K filing highlights the company's focus on its obesity portfolio, progress in clinical trials, and financial activities including securities offerings and a potential Cortigent spin-off.

Summary

• Vivani Medical, a clinical-stage biopharmaceutical company, focuses on developing miniaturized, subdermal drug implants using its NanoPortal technology for chronic diseases.
• The company's lead programs include NPM-115 (exenatide) and NPM-139 (semaglutide) for chronic weight management, with NPM-115 currently in clinical trials in Australia and expected to report top-line data in mid-2025.
• NPM-139, a semaglutide implant, is in preclinical development and has shown encouraging weight loss data, with the potential for once-yearly dosing.
• Vivani is also developing NPM-119 (exenatide) for type 2 diabetes and OKV-119 (GLP-1) for cardiometabolic disorders in cats, in partnership with Okava Pharmaceuticals.
• The company is considering developing a semaglutide implant for type 2 diabetes.
• Vivani was formed through the merger of Second Sight Medical Products and Nano Precision Medical in August 2022.
• In March 2025, Vivani announced a change in strategy to discontinue efforts to pursue a proposed initial public offering and shift focus to file a Form 10 with the SEC to support the spin-off of Cortigent into a fully independent, publicly traded company.
• In March 2024, Vivani entered into a securities purchase agreement for $15 million and an open market sale agreement with Jefferies LLC for up to $75 million.
• In November 2024, the company entered into a private sale transaction with one of its independent directors for $5.0 million.
• In March 2025, the company entered into a private sale transaction with an entity affiliated with one of its independent directors for $8.25 million.
• The company's proprietary NanoPortal implant technology enables ultra long-acting, near constant-rate drug delivery.
• Vivani initiated its first-in-human clinical trial (LIBERATE-1) for NPM-115 in obese and overweight individuals in Australia, with results expected in mid-2025.
• The company believes its NanoPortal technology can address poor medication adherence and improve patient tolerability, particularly for GLP-1 therapies.
• Vivani faces competition from other pharmaceutical and biotechnology companies in the treatment of obesity and type 2 diabetes.
• The company's strategy includes clinical and regulatory development of its lead programs, expanding its portfolio, developing manufacturing capabilities, and protecting its intellectual property.
• Vivani aims to reduce medical waste through development and commercialization of its NanoPortal implant technology.
• The company maintains its headquarters and operations in California, complying with sustainability standards and promoting employee commuting pollution mitigation.
• Vivani had 36 employees in its Biopharm Division and 6 employees in Cortigent as of December 31, 2024.
• The company is involved in legal proceedings, including an appeal against a judgment from the Paris Commercial Court related to a terminated MOU with Pixium Vision.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive developments in clinical trials and strategic shifts, the company's financial situation and ongoing legal proceedings introduce uncertainty.

Positives

• Prioritization of obesity portfolio reflects a strategic focus on a high-growth market.
• Clinical trials for NPM-115 are underway, indicating progress in the development pipeline.
• Encouraging preclinical data for NPM-139 suggests potential for a differentiated product with convenient dosing.
• NanoPortal technology addresses a key challenge in chronic disease management: medication adherence.
• Potential spin-off of Cortigent could unlock value and allow for greater focus on core therapeutic areas.
• Recent capital raises provide funding for ongoing operations and clinical development.
• Positive preclinical liver fat results with its miniature, ultra long-acting GLP-1 implant.

Negatives

• The company has a history of recurring operating losses and negative operating cash flows.
• The company is dependent on raising additional capital to fund its operations.
• The company is involved in legal proceedings, including an appeal against a judgment from the Paris Commercial Court related to a terminated MOU with Pixium Vision.
• The company is a clinical-stage company with no products approved for commercial sale.

Risks

• The company is dependent on the successful development, regulatory approval, and commercialization of its product candidates.
• Clinical development involves a lengthy and expensive process with uncertain outcomes.
• The commercial success of product candidates depends on market acceptance among physicians, patients, and healthcare payors.
• The company is subject to manufacturing challenges and reliance on third parties.
• The company may not be able to adequately protect its proprietary or licensed technology.
• The company may infringe the intellectual property rights of others.
• The company may be unable to adequately prevent disclosure of trade secrets and other proprietary information.
• The company's ability to utilize its net operating loss (NOL) carry-forwards and certain other tax attributes may be limited.
• The company may experience delays in the enrollment of patients in its clinical trials.
• The company may experience difficulty identifying, training and/or certifying an adequate number of healthcare professionals to properly implant and, when appropriate, explant our drug implants candidates, which may impair our ability to conduct our clinical trials.
• The company may not be able to complete the spin-off of Cortigent on the terms anticipated or at all.

Future Outlook

Vivani anticipates reporting top-line data from the LIBERATE-1 clinical trial in mid-2025 and plans to continue developing its pipeline of drug implant candidates.

Industry Context

The announcement highlights Vivani's participation in the competitive GLP-1 market, which is experiencing significant growth due to the increasing prevalence of obesity and type 2 diabetes. The company's focus on long-acting implants aims to address the limitations of existing oral and injectable therapies.

Comparison to Industry Standards

• The document mentions competitors like Novo Nordisk and Eli Lilly, which have established GLP-1 products such as Ozempic, Wegovy, and Mounjaro.
• Vivani's approach with NanoPortal technology aims to differentiate itself by improving medication adherence and tolerability, addressing issues seen with existing GLP-1 therapies like Intarcia's ITCA 650.
• The company's preclinical weight loss data with exenatide implants is compared to semaglutide injections, indicating a potential for similar efficacy.
• The document references a patient preference study testing a product profile reflective of both ITCA 650 and NPM-119 (e.g. miniature, six-month, subdermal, GLP-1 implant).
• The document references FDA's Open Public Hearing on September 28, 2023 to review Intarcia's ITCA 650 ( exenatide implant).

Legal Proceedings

• Three oppositions filed by Pixium Vision are pending in the European Patent Office, each challenging the validity of a European patent owned by Cortigent.
• The Company is party to litigation arising in the ordinary course of business.
• On May 19, 2021, Pixium filed suit in the Paris Commercial Court, and currently claim damages of approximately 5.1 million or about $5.6 million.
• On December 8, 2022, the Company received notice that the Paris Commercial Court has rendered its judgement, including finding that the Companys termination of the MOU was not valid.
• On May 24, 2023, the Company filed an appeal against the judgment from the Paris Commercial Court.
• On October 23, 2024, the pre-trial judge issued his order, striking out Vivani's appeal for failure to enforce the decision.

Related Party Transactions

• On November 8, 2024, the Company entered into a private sale transaction with one of its independent directors whereby the Company sold an aggregate of 3,968,253 shares of the Companys common stock to the director at a price of $1.26 per share.
• On March 26, 2025, the Company entered into a private sale transaction with an entity affiliated with one of its independent directors whereby the Company shall sell an aggregate of 7,366,071 shares of the Companys common stock to the entity at a price of $1.12 per share.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from the company's commitment to providing competitive compensation and benefits.
• Patients may benefit from the development of new and improved treatments for chronic diseases.
• The company's commitment to environmental sustainability may positively impact the environment and society.

Next Steps

• Report top-line data from the LIBERATE-1 clinical trial in mid-2025.
• Continue advancing the feasibility assessments of NPM-139 (semaglutide implant) for the treatment of obesity and chronic weight management.
• Continue developing manufacturing capabilities and systems at Vivani's dedicated facility in Alameda, CA to produce clinical trial supply.
• Leverage the company's proprietary NanoPortal platform technology to expand our emerging portfolio of innovative drug implants to improve the treatment of chronic diseases.
• Maintain, expand, and protect our intellectual property portfolio.
• Add operational, financial, and management information systems and personnel, including personnel to support its planned product development efforts, as well as to support its regulatory responsibilities as a public reporting company.

Key Dates

Keywords

GLP-1, implants, obesity, weight management, NanoPortal, clinical trials, biopharmaceutical, exenatide, semaglutide, Vivani Medical